kabutan

Pharma Foods, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 33%

Fri Mar 13, 2026 1:30 pm JST Earnings

2929 Pharma Foods International Co., Ltd. 【J-GAAP】

Earnings Report

Pharma Foods International Co., Ltd. <2929> [TSE Prime] announced its financial results in the afternoon session on March 13th (13:30). The consolidated ordinary profit/loss for the cumulative second quarter of the fiscal year ending July 2026 (August 2025 to January 2026) turned into a loss of 2.43 billion yen (compared to a profit of 0.64 billion yen in the same period last year).

However, the full-year forecast for consolidated ordinary profit has been revised upward 33.3%, from the previous forecast of 1.50 billion yen to 2.00 billion yen (compared to 2.55 billion yen in the previous period), and the declining rate is expected to decrease from 41.2% to 21.7%.

Based on the first-half performance announced by the company and the full-year plan, our calculation indicates that the consolidated ordinary profit for the February to July period (second half) is expected to surge 2.3 times that of the same period last year, reaching 4.43 billion yen.

In the most recent three-month period, from November to January (2Q), the consolidated ordinary profit/loss turned to a profit of 0.20 billion yen (compared to a loss of 0.24 billion yen in the same period last year). The operating profit/loss margin improved from -1.7% in the same period last year to 0.9%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Aug - Jan, 2023 31,652 1,535 1,542 768 26.7 29.4 Mar 11, 2024 J-GAAP
Aug - Jan, 2024 29,857 623 645 229 8.1 25.3 Mar 12, 2025 J-GAAP
Aug - Jan, 2025 32,441 -2,361 -2,437 -1,824 -63.1 ー Mar 13, 2026 J-GAAP
YoY +8.7% － － － －

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Aug - Jan, 2025 Guidance ー ー ー ー － 12.50 Sep 11, 2025 J-GAAP
Aug - Jan, 2025 Results 32,441 -2,361 -2,437 -1,824 -63.1 12.50 Mar 13, 2026 J-GAAP
Revision Rate － － － － －

Guidance Update

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul, 2026 Prev 68,000 1,500 1,500 1,000 34.4 25 Sep 11, 2025 J-GAAP
Jul, 2026 New 67,000 2,000 2,000 1,500 51.7 25 Mar 13, 2026 J-GAAP
Revision Rate -1.5% +33.3% +33.3% +50.0% +50.0%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Feb - Jul, 2025 35,403 1,744 1,908 139 4.9 12.50 Sep 11, 2025 J-GAAP
Feb - Jul, 2026 Guidance 34,559 4,361 4,437 3,324 114.5 12.50 Mar 13, 2026 J-GAAP
YoY -2.4% +150.1% +132.5% +2,291.4% +2,260.0%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul, 2024 62,147 5,113 5,249 3,205 112.7 25 Sep 12, 2024 J-GAAP
Jul, 2025 65,260 2,367 2,553 368 12.8 25 Sep 11, 2025 J-GAAP
Jul, 2026 Guidance 67,000 2,000 2,000 1,500 51.7 25 Mar 13, 2026 J-GAAP
YoY +2.7% -15.5% -21.7% +307.6% +302.6%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Nov - Jan, 2024 15,261 -259 -243 -131 -4.6 -1.7 Mar 12, 2025 J-GAAP
Feb - Apr, 2025 16,960 -840 -876 -1,352 -47.2 -5.0 Jun 10, 2025 J-GAAP
May - Jul, 2025 18,443 2,584 2,784 1,491 52.0 14.0 Sep 11, 2025 J-GAAP
Aug - Oct, 2025 15,712 -2,511 -2,644 -1,891 -65.5 -16.0 Dec 11, 2025 J-GAAP
Nov - Jan, 2025 16,729 150 207 67 2.3 0.9 Mar 13, 2026 J-GAAP
YoY +9.6% － － － －

Related Articles